These featured cancer clinical trials are currently open at the UCI Health Chao Family Comprehensive Cancer Center.

To refer a patient or get more information about a clinical trial, click on the principal investigator’s name to send an email. You may also contact us at ucstudy@uci.edu or 877-UC-Study. To search all cancer clinical trials now available at UCI Health, visit cancer.uci.edu/clinical-trials-flowcharts

**Brain and nervous system**

A multicenter, open-label study with a randomized control arm of the efficacy, safety and pharmacokinetics of intravenously infused berubicin in adult patients with recurrent glioblastoma multiforme (WHO grade 4) after failure of standard first-line therapy (UCI 21-18/CNS-201)

*For more information, contact principal investigator Daniela Bota, MD*

A phase 1b trial of CB-839 in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (ETCTN-10218)

*For more information, contact principal investigator Xiao-Tang Kong, MD*

**Breast**

A randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) +
tremelimumab in patients with metastatic triple-negative breast cancer (ETCTN-10146)
For more information, contact principal investigator Ritesh Parajuli, MD

EMBER: a phase 1a/1b study of LY3484356 administered as monotherapy and in combination with abemaciclib to patients with ER+, HER2 locally advanced or metastatic breast cancer and other select non-breast cancers. (UCI 20-60/J2J-MC-JZLA)
For more information, contact principal investigator Ritesh Parajuli, MD

COVID-19

NCI COVID-19 in Cancer Patients Study (NCCAPS): a longitudinal natural history study (NCICovid)
For more information, contact principal investigator Hannah Hyochan Nam, MD

Gastrointestinal

A prospective, open-label, randomized trial to assess the safety and efficacy of the CG-100 intraluminal bypass device for reducing stoma creation rate in colorectal and coloanal anastomoses (UCI 20-163/CLD-075)
For more information, contact principal investigator Joseph Carmichael, MD

A phase 2/3 study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage IIA colon cancer (COBRA) (NRG-GI005)
For more information, contact principal investigator Jason Zell, DO

Genitourinary

A phase 1b/2 trial of pembrolizumab (MK-3475) combination therapies in metastatic, castration-resistant prostate cancer (mCRPC) (KEYNOTE-365) (UCI 16-76/MK-3475-365)
For more information, contact principal investigator Nataliya Mar, MD

A phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG) (UCI 20-91/CG2003C)
For more information, contact principal investigator Edward Uchio, MD

A master protocol evaluating the safety and efficacy of therapies for metastatic,
castration-resistant prostate cancer (mCRPC) (UCI 21-07/20190505)

For more information, contact principal investigator Arash Rezazadeh Kalebasty, MD

Gynecologic oncology

A randomized, controlled, double-arm, double-blind, multicenter study of ofranergene obadenovec (VB-111) combined with paclitaxel vs. paclitaxel combined with placebo for the treatment of recurrent platinum-resistant ovarian cancer (OVAL) (GOG-3018/VB-111-701)

For more information, contact principal investigator Krishnansu Tewari, MD

A phase 2, randomized study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or platinum-refractory ovarian cancer (ETCTN-10150)

For more information, contact principal investigator Jill Tseng, MD

Head and neck

Randomized phase 2 and phase 3 studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) (HN001)

For more information, contact principal investigator Rupali Nabar, MD

A randomized phase 2/3 trial of adjuvant radiation therapy with cisplatin, docetaxel-cetuximab or cisplatin-atezolizumab in pathologic, high-risk squamous cell cancer of the head and neck (RTOG-1216)

For more information, contact principal investigator Rupali Nabar, MD

Hematologic malignancies

A phase 2, open-label, multicenter, nonrandomized study of PF-06863135 monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody (UCI 21-116/C1071003)

For more information, contact principal investigator Lisa Lee, MD

A phase 3, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of tafasitamab plus lenalidomide in addition to rituximab vs. lenalidomide in addition to rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) grade 1-3A or R/R marginal zone lymphoma (MZL) (UCI 20-
For more information, contact principal investigator Elizabeth Brém, MD

**Hepatobiliary**

A phase 1 study of anetumab ravtansine in combination with either anti-PD-1 antibody, or anti-CTLA4 and anti-PD-1 antibodies, or anti-PD-1 antibody and gemcitabine in mesothelin-positive, advanced pancreatic adenocarcinoma (ETCTN-10208)

For more information, contact principal investigator Farshid Dayyani, MD

A phase 1b/2, open-label, multicenter, randomized, umbrella study evaluating the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with advanced liver cancers (Morpheus liver) (UCI 20-79/GO42216)

For more information, contact principal investigator Farshid Dayyani, MD

**Lung**

A phase 2 study of nivolumab plus relatlimab in combination with chemotherapy vs. nivolumab in combination with chemotherapy as first-line treatment for subjects with stage IV or recurrent non-small cell lung cancer (NSCLC) (UCI 20-158/CA224-104)

For more information, contact principal investigator Sai-Hong Ou, MD

A phase 1/2 study of the selective RET inhibitor TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities (UCI 20-133/HM06-19-26)

For more information, contact principal investigator Sai-Hong Ou, MD

**Skin**

A phase 1/2 study of dabrafenib, trametinib and navitoclax in BRAF-mutant melanoma (phase 1 and 2) and other solid tumors (phase 1 only) (ETCTN-9466)

For more information, contact principal investigator Justin Moyers, MD

A phase 1/2, open-label, multicenter study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors (UCI 18-64/RPL-001-16(IGNYTE))

For more information, contact principal investigator John Fruehauf, MD
As an NCI-designated comprehensive cancer center, the UCI Chao Family Comprehensive Cancer Center conducts many clinical trials. By participating in a clinical trial, your patients have access to leading-edge treatments and therapies long before they are available to the general public. According to the National Comprehensive Cancer Network (NCCN) guidelines, the best management for any cancer patient is on a clinical trial.